Valeric Acid

Valeric Acid

SCHEMBL446967

CCCCC(=O)[O-].CCCCn1cc[n+](C)c1

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.59
HSP90AA1 P07900 2/20 0.59
KMT2A Q03164 2/20 0.59
SMN1; SMN2 Q16637 2/20 0.59
APAF1 O14727 1/20 0.59
NPC1 O15118 1/20 0.59
PLA2G1B P04054 1/20 0.59
MAPT P10636 1/20 0.59
MAPK1 P28482 1/20 0.59
HTT P42858 1/20 0.59
RAB9A P51151 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
ATG4B Q9Y4P1 1/20 0.59
CA1 P00915 1/20 0.47
FDPS P14324 13/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hexanoate SCHEMBL19406560 0.95 MEN1 (0.62) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Succinic Acid SCHEMBL18575092 0.95 MEN1 (0.61) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Octanoic Acid SCHEMBL3125481 0.94 MEN1 (0.65) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Dodecanoate SCHEMBL31549880 0.94 MEN1 (0.65) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Butyric Acid SCHEMBL507693 0.94 MEN1 (0.59) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Palmitic Acid SCHEMBL28783471 0.91 MEN1 (0.69) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Myristic Acid SCHEMBL28783475 0.91 MEN1 (0.69) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Palmitic Acid SCHEMBL28783451 0.91 MEN1 (0.69) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Myristic Acid SCHEMBL28783522 0.91 MEN1 (0.69) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1
Dodecanoate SCHEMBL28783503 0.91 MEN1 (0.69) MEN1HSP90AA1KMT2ASMN1; SMN2APAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8674121-B2 Process for the production of benzofurans SANOFI (FR) 2014-03-18 US disclosed
EP-2435398-B1 PROCESS FOR THE PRODUCTION OF BENZOFURANS SANOFI SA (FR) 2014-01-22 EP disclosed
US-20120065411-A1 PROCESS FOR THE PRODUCTION OF BENZOFURANS SANOFI (FR) 2012-03-15 US disclosed
WO-2010136500-A1 PROCESS FOR THE PRODUCTION OF BENZOFURANS SANOFI-AVENTIS (FR) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065411-A1 PROCESS FOR THE PRODUCTION OF BENZOFURANS CYP2F1, CYP2B6, CYP4F2 MEN1 4303/4885HSP90AA1 355/4885KMT2A 2431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.